Items where authors include "Butler, R"

Article

McArthur, AD orcid.org/0000-0002-7245-9465, Gamberi, F, Maniscalco, R et al. (1 more author) (2022) Editorial: Source or sink? Erosional and depositional signatures of tectonic activity in deep-sea sedimentary systems. Frontiers in Earth Science, 10. 1042473. ISSN 2296-6463

Howell, SJ, Casbard, A, Carucci, M et al. (14 more authors) (2022) Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. The Lancet Oncology, 23 (7). pp. 851-864. ISSN 1470-2045

Brown, LC, Graham, J, Fisher, D et al. (15 more authors) (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19 (2). pp. 146-157. ISSN 1740-7745

Richman, SD orcid.org/0000-0003-3993-5041, Hemmings, G, Roberts, H et al. (12 more authors) (2022) FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing. Journal of Clinical Pathology. ISSN 0021-9746

Seligmann, JF, Fisher, DJ, Brown, LC et al. (19 more authors) (2021) Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. Journal of Clinical Oncology, 39 (33). pp. 3705-3715. ISSN 0732-183X

Adams, RA, Fisher, DJ, Graham, J et al. (19 more authors) (2021) Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. Journal of Clinical Oncology. JCO.21.01436-JCO.21.01436. ISSN 0732-183X

Suen, KM, Braukmann, F, Butler, R et al. (9 more authors) (2020) DEPS-1 is required for piRNA-dependent silencing and PIWI condensate organisation in Caenorhabditis elegans. Nature Communications, 11. 4242. ISSN 2041-1723

Hausenloy, DJ, Kharbanda, RK, Møller, UK et al. (40 more authors) (2019) Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. The Lancet, 394 (10207). pp. 1415-1424. ISSN 0140-6736

Dennis, M, Mead, G, Forbes, J et al. (1294 more authors) (2019) Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. The Lancet, 393 (10168). pp. 265-274. ISSN 0140-6736

Lindsay, CR, Shaw, EC, Blackhall, F et al. (26 more authors) (2018) Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. Esmo Open, 3 (6). e000408. ISSN 2059-7029

Annels, NE, Arif, M, Simpson, GR et al. (11 more authors) (2018) Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus. Molecular Therapy - Oncolytics, 9. C. pp. 1-12. ISSN 2372-7705

Adams, R, Brown, E, Brown, L et al. (14 more authors) (2018) Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial. Lancet Gastroenterology and Hepatology, 3 (3). pp. 162-171. ISSN 2468-1253

Richman, SD orcid.org/0000-0003-3993-5041, Fairley, J, Butler, R et al. (1 more author) (2017) RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009–2016). Virchows Archiv, 471 (6). pp. 721-729. ISSN 0945-6317

Richman, SD orcid.org/0000-0003-3993-5041, Fairley, J, Butler, R et al. (1 more author) (2017) How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation. Journal of Clinical Pathology, 70 (1). pp. 58-62. ISSN 0021-9746

Richman, SD, Adams, R, Quirke, P et al. (10 more authors) (2016) Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. Journal of Clinical Pathology, 69 (1). pp. 35-41. ISSN 0021-9746

Maughan, TS, Meade, AM, Adams, RA et al. (22 more authors) (2014) A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? British Journal of Cancer, 110 (9). 2178 - 2186. ISSN 0007-0920

Conference or Workshop Item

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

Adams, R, Fisher, D, Graham, J et al. (13 more authors) (2021) Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial. In: 2021 ASCO Annual Meeting I, 04-08 Jun 2021, Online.

Proceedings Paper

Jones, RH, Carucci, M, Casbard, AC et al. (10 more authors) (2019) Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER -positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial. In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology .

Richman, SD orcid.org/0000-0003-3993-5041, Adams, R, Brown, E et al. (14 more authors) (2017) FOCUS4: MAMS Trial Design in Action. Early Closure of FOCUS4-D (Pan-HER 1, 2 and 3 Inhibitor Versus Placebo) in Advanced Colorectal Cancer (aCRC) Patients, with Tumours Wildtype (WT) for KRAS, NRAS, bRAF and PIK3CA. In: Journal of Pathology. Belfast Pathology 2017: 10th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 20-23 Jun 2017, Belfast, Northern Ireland, UK. Wiley , S13-S13.

Adams, RA, Brown, E, Brown, L et al. (13 more authors) (2016) FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS. In: Annals of Oncology. 41st ESMO Congress (ESMO 2016), 07-11 Oct 2016, Copenhagen. Oxford University Publishing .

Seligmann, JF, Fisher, D, Elliott, F et al. (8 more authors) (2015) Exploring the poor outcomes of BRAF mutant (BRAF mut) advanced colorectal cancer (aCRC): Analysis from 2,530 patients (pts) in randomized clinical trials (RCTs). In: Journal of Clinical Oncology. 2015 ASCO Annual Meeting, 29 May - 02 Jun 2015, Chicago, IL. American Society of Clinical Oncology .